Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers

PURPOSE: Although both anti-PD-1 antibody and treatments using anti-PD-L1 antibody are currently in clinical use, their therapeutic effects vary according to cancer type. One of the factors accounting for this variability is the expression level of the immune checkpoint molecule that differs between...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshida, Kazushige, Okamoto, Masanori, Sasaki, Jun, Kuroda, Chika, Ishida, Haruka, Ueda, Katsuya, Okano, Satomi, Ideta, Hirokazu, Kamanaka, Takayuki, Sobajima, Atsushi, Takizawa, Takashi, Kito, Munehisa, Aoki, Kaoru, Uemura, Takeshi, Haniu, Hisao, Kato, Hiroyuki, Saito, Naoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452806/
https://www.ncbi.nlm.nih.gov/pubmed/31040694
http://dx.doi.org/10.2147/OTT.S198421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452806/
https://www.ncbi.nlm.nih.gov/pubmed/31040694
http://dx.doi.org/10.2147/OTT.S198421

Ejemplares similares